GE Healthcare (NYSE:GE) announced today that it made the Serena Bright biopsy technology available in the U.S.
Chicago-based GE Healthcare touts Serena Bright as the industry’s first contrast-enhanced guided biopsy solution, according to a news release. The technology is designed to help clinicians and patients in the fight against breast cancer.
Serena Bright received FDA 510(k) clearance in June as a platform for conducting breast biopsy exams with contrast guidance using the same mammography equipment in the same room and with the same staff as the screening or diagnostic mammogram.
The system is also intended to help with delays in diagnoses due to the backlog of screenings because of the COVID-19 pandemic. GE Healthcare said it could allow for follow-up biopsy procedures to be done in a matter of days instead of over several weeks, as can be the case with MRI biopsy.
GE Healthcare’s system includes SenoBright HD CESM, a diagnostic breast exam with iodine-based contrast that offers high sensitivity for more accurate breast cancer diagnosis. It also highlights areas of unusual blood flow to localize lesions that need to be biopsied, which creates better image quality to help with clinical confidence.
“Now more than ever, it is critical we put the comfort of patients first and get them answers as fast as possible,” GE Healthcare president & CEO of women’s health & X-ray Agnes Berzsenyi said in the release. “We are proud to bring Serena Bright to our customers during a time when this type of innovation is needed most. We hope this technology can help improve breast cancer outcomes for women during this time of uncertainty.”
Jefferson Health in Philadelphia became the first healthcare system in the U.S. to offer this technology, while the company said healthcare providers around the world are now looking to implement the platform.
